B O O K - American College of Rheumatology

ACR Poster Session B
1084. Gene Expression Profiling in Rheumatoid Arthritis Patients
Following B Cell Depletion with Rituximab Reveals Changes in
Type I IFN Activity Related to Clinical Responsiveness. Saskia
Vosslamber 1 , Hennie G. Raterman 2 , Tineke C. T. M. van der
PouwKraan 2 , Micheal T. Nurmohamed 2 , Willem F. Lems 2 , Ben A.
C. Dijkmans 2 , Alexandre E. Voskuyl 2 and Cornelis L. Verweij 2 , 1 VU
University Medical Center, Amsterdam, The Netherlands, 2 VU
University Medical Center.
1085. Heterogeneity in the Bone Marrow B Cell Compartment:
Implications for Pathogenesis of Human RA. Arumugam
Palanichamy, Chris Cistrone, Jennifer Hossler, Chungwen Wei,
James Kobie, Inaki Sanz and Jennifer Anolik, University of
Rochester Medical Center.
1086. High Level of Serum Matrix Metalloproteinase-3 Could Be
Implicated in the Pathogenesis of Rheumatoid Interstitial
Lung Disease. Yoshinobu Koyama 3 , Kosuke Tsuruno 1 , Toshiyuki
Ota 2 and Kenji Fujii 1 , 1 Center for Rheumatic Diseases, Iizuka
Hospital, 2 Department of Laboratory and Transfusion Medicine,
University of Occupational and Environmental Health, 3 Iizuka
Hospital, Iizuka, Japan.
1087. Identification of Genes Associated with Erosion in Cohorts
of Patients with Early Arthritis. Amir Kadi 5 , Brigitte Izac 5 ,
Jean-Philippe Jais 3 , Thierry Lequerre 4 , Olivier Vittecoq 4 , Xavier
Le Loet 4 , Philippe Dieude 1 , Corinne Miceli 3 , Maxime Breban 2
and Gilles Chiocchia 5 , 1 AP-HP, Paris, France, 2 AP-HP, Boulogne-
Billancourt, France, 3 AP-HP, 4 CHU Rouen, 5 Inserm U1016 / CNRS
UMR8104, Paris, France.
1088. In Early RA, Serum Increase of IL-21 Is Associated with
Serum Level of IL-6, Autoantibody Secretion, Markers of
B-Cell Activation, and Radiographic Progression. Jacques-Eric
Gottenberg 4 , Pascale Roux-Lombard 2 , Alain Cantagrel 5 , Alain
Saraux 1 , Cedric Lukas 3 , Jean-Michel Dayer 2 and Xavier Mariette,
1
Brest Hospital, 2 Geneva Hospital, 3 Montpellier Hospital,
4
Strasbourg Hospital, 5 Toulouse Hospital.
1089. Strong Activation of Dopamine Pathway in Synovial Tissue
from Rheumatoid Arthritis Patients: New Target of Pathology?
Silvia Capellino 1 , Christine Wolff 2 , Franca Marino 3 , Alessandra
Luini 3 , Marco Cosentino 3 and Rainer H. Straub 1 , 1 University
Hospital Regensburg, Dept. of Internal Medicine I, Regensburg,
Germany, 2 University Hospital Regensburg, Dept. of Internal
Medicine I, Regensburg, Germany, 3 University of Insubria,
Varese, Italy.
1090. T-Cell Subsets Dys-Regulation and Cytokines Are Predictive
of RA Pathogenesis in an ACPA-Positive Background. Richard
Cuthbert 2 , Rekha Parmar 2 , Jackie Nam 2 , Edith Villeneuve 2 , Diane
Corscadden 2 , Karen Henshaw 2 , Paul Emery 1 and Frederique
Ponchel 2 , 1 Chapel Allerton Hospital, Leeds, United Kingdom,
2
University of Leeds.
1091. The Development of the ACPA Repertoire Prior to the Onset
of Clinical RA. Lotte A. van de Stadt 4 , Margret de Koning 2 , Rob
J. van de Stadt 1 , Gertjan Wolbink 2 , B. A. C. Dijkmans 5 , Dörte
Hamann 3 and Dirkjan van Schaardenburg 2 , 1 Jan van Breemen
Institiute, 2 Jan van Breemen Institute, 3 Sanquin Diagnostics,
4
Sanquin Research, 5 VU Medical Centre, Amsterdam, The
Netherlands.
1092. The Differential Effect of HLA-DRB1 *0901 Allele from Shared
Epitope on the Development of Rheumatoid Arthritis. So-
Young Bang 1 , Hye-Soon Lee 1 , Ji-Seon Lee 1 , Eun-Mi Kim 1 , Kyung
Wha Lee 2 and Sang-Cheol Bae 1 , 1 Department of Rheumatology,
Hanyang University Hospital for Rheumatic Diseases, Korea,
Republic of, 2 Hallym Institute for Genome Application, Hallym
University Sacred Heart Hospital, Anyang, Korea, Republic of.
1093. The Smoking-Induced Heat Shock Protein DNAjC6 Is
Downregulated in Rheumatoid Arthritis. Caroline Ospelt 1 ,
Joanna Stanczyk 2 , Christoph Kolling 3 , Renate E. Gay 1 and Steffen
Gay 4 , 1 Center of Experimental Rheumatology and Center of
Integrative Human Physiology, Zurich, Switzerland, 2 Center of
Experimental Rheumatology and Center of Integrative Human
Physiology, Zurich, Switzerland, 3 Schulthess Clinic Zurich,
Switzerland, 4 University Hospital Zurich, Zurich, Switzerland.
1094. Variability of Anti-CCP Kit Testing in Cohorts with and without
RA. Kevin D. Deane 7 , Kristen Demoruelle 10 , Mark Parish 4 ,
Whitney Hilton 4 , Lauren Harrington 4 , Lezlie Derber 4 , Jason R.
Kolfenbach 6 , Jan M. Hughes-Austin 4 , Michael H. Weisman 3 ,
Ted R. Mikuls 14 , James R. O’Dell 8 , Richard M. Keating 1 , Peter K.
Gregersen 5 , Jane Buckner 2 , Irene Smolik 13 , Donna Hart 13 , Charles
N. Bernstein 13 , David B. Robinson 12 , Jill Norris 9 , V. Michael
Holers 7 and Hani S. El-Gabalawy 11 , 1 Oak Park, IL, 2 Benaroya
Research Institute at Virginia Mason, Seattle, WA, 3 Cedars-Sinai
Medical Center, Los Angeles, CA, 4 Division of Rheumatology,
University of Colorado School of Medicine, Aurora, CO, 5 N
Shore Univ Hosp Rsch Ctr, Manhasset, NY, 6 Univ of CO Schl of
Med, Aurora, CO, 7 Univ of Colorado School of Med, Aurora, CO,
8
University of Nebraska Medical Center, Omaha, NE, 9 University
of Colorado Denver, Aurora, CO, 10 University of Colorado School
of Medicine, 11 University of Manitoba, Winnipeg, MB, Canada,
12
University of Manitoba, Winnipeg, MB, Canada, 13 University of
Manitoba, 14 University of Nebraska Medical Center, Omaha, NE.
Rheumatoid Arthritis Treatment - Small Molecules, Biologics
and Gene Therapy: Predicting and Measuring Outcomes, Novel
Compounds II
1095. A Phase IIa, Randomized, Double-Blind, Placebo-Controlled
Clinical Study of Apilimod Mesylate, an Oral IL-12/IL-23
Inhibitor, in Patients with Active Rheumatoid Arthritis. Sarah
Krausz 3 , Maartje J. H. Boumans 3 , Daniëlle M. Gerlag 3 , Joelle
Lufkin 4 , Arno W. R. van Kuijk 2 , Alian A. B. Bakker 3 , Maarten de
Boer 3 , Beatrijs M. Lodde 3 , Kris A. Reedquist 3 , Eric W. Jacobson 4 ,
Michael O’Meara 4 and Paul P. Tak 1 , 1 Academic Med Ctr/Univ of
Amsterdam, Amsterdam, The Netherlands, 2 Academic Medical
Center/University of Amsterdam, 3 Academic Medical Center-
University of Amsterdam, 4 Synta Pharmaceuticals Corp.
1096. ALD518 (BMS945429), a High-Affinity Anti-Interleukin-6
Monoclonal Antibody, Provides Improvements in Health-
Related Quality of Life (HRQoL) in Patients with Rheumatoid
Arthritis (RA) and an Inadequate Response to Methotrexate.
Vibeke Strand 3 , Levan Shalamberidze 6 , Aleksandar Dimic 4 ,
Jeffrey Smith 1 , Robin Mukherjee 2 and Philip Mease 5 , 1 Alder
Biopharmaceuticals Inc., Bothell, WA, 2 Bristol-Myers Squibb,
Princeton, NJ, 3 Division of Immunology/Rheumatology, Stanford
University, Palo Alto, CA, 4 Institute of Rehabilitation and
Treatment, Niska Banja, Serbia, 5 Swedish Medical Center and
University of Washington, Seattle, WA, 6 V. Tsitlanadze Scientific
Practical Centre of Rheumatology, Tbilisi, Georgia.
1097. Assessment of Inflammation and Damage by MRI in
Established RA Patients with Methotrexate Inadequate
Response Receiving Golimumab: Results of the GO-FORWARD
Trial. Philip G. Conaghan 3 , Paul Emery 4 , Mikkel Østergaard 5 ,
Ed C. Keystone 8 , Mark C. Genovese 7 , Lars Klareskog 6 , Weichun
Xu 1 , Elizabeth C. Hsia 2 and Mahboob U. Rahman 2 , 1 Centocor
Research and Development, Inc., 2 Centocor Research and
Development, Inc./Univ. of Pennsylvania School of Medicine,
Malvern, PA, 3 Chapel Allerton Hospital, Leeds, United Kingdom,
4
Chapel Allerton Hospital, Leeds, United Kingdom, 5 Copenhagen
University Hospital at Glostrup and Hvidovre, 6 Karolinska
University Hospital, Stockholm, Sweden, 7 Stanford University,
Sunnyvale, CA, 8 University of Toronto, Toronto, ON, Canada.
2010 Program Book 215